Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer


PURPOSE To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. EXPERIMENTAL DESIGN The HR status of 12 OCCC cell lines was determined using RAD51/γH2AX foci formation assays. Sensitivity to cisplatin and… (More)
DOI: 10.18632/oncotarget.14011


3 Figures and Tables